Tag Archive for: STC-15

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium

/in

STC-15 is the first METTL3 inhibitor to enter clinical development Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients 9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

/in

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce that its Founder & Director and Professor of Cancer Biology, University of Cambridge, UK, Tony Kouzarides, […]

Read more

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

/in

STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies 3 June 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, […]

Read more

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

/in

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity 24 May 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it will be presenting interim clinical data on its […]

Read more

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/in

STORM’s first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase STC-15 reshapes the tumour microenvironment and activates anti-tumour immunity 17 October 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, […]

Read more
© Optimum Strategic Communications.